Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cymabay Therapeutics
(NQ:
CBAY
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cymabay Therapeutics
< Previous
1
2
3
4
Next >
Analyst Expectations for CymaBay Therapeutics's Future
August 31, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023
August 14, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
August 11, 2023
Via
Benzinga
Earnings Preview For CymaBay Therapeutics
August 09, 2023
Via
Benzinga
7 Analysts Have This to Say About CymaBay Therapeutics
July 31, 2023
Via
Benzinga
Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
July 13, 2023
HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of
Via
Benzinga
Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
June 30, 2023
Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 30, 2023
Via
Benzinga
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 30, 2023
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top...
Via
Benzinga
Why Shares of CymaBay Therapeutics Are Soaring Friday
June 30, 2023
A competitor's drug had a so-so phase 3 trial, lifting the possibilities for CymaBay's lead therapy.
Via
The Motley Fool
Analyst Expectations for CymaBay Therapeutics's Future
June 26, 2023
Via
Benzinga
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
June 30, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Dow Surges 200 Points; Constellation Brands Posts Upbeat Results
June 30, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 200 points on Friday. Following the market opening Friday, the Dow traded up 0.63% to 34,338.23 while the NASDAQ rose 1.05%...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 30, 2023
Via
Benzinga
Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug
June 23, 2023
Following the FDA rejection, Intercept will restructure to focus on rare liver diseases.
Via
Investor's Business Daily
Expert Ratings for CymaBay Therapeutics
May 16, 2023
Via
Benzinga
CymaBay Therapeutics: Q1 Earnings Insights
May 15, 2023
Via
Benzinga
CymaBay Therapeutics's Earnings Outlook
May 12, 2023
Via
Benzinga
The Latest Analyst Ratings for CymaBay Therapeutics
April 24, 2023
Via
Benzinga
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
May 22, 2023
On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid...
Via
Benzinga
Why CymaBay Therapeutics Stock Nose-Dived This Week
May 19, 2023
Investors did not warmly greet the latest news from the biotech.
Via
The Motley Fool
Four Potential Breakout Stocks For The Rest Of The Week
April 19, 2023
In trading, there will always be elegance in simplicity. If your trading operation lacks a cadre of PhDs to crunch data like Renaissance Technologies or D.E. Shaw, simplicity will always trump...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 5, 2023
April 05, 2023
Via
Benzinga
Analyst Ratings for CymaBay Therapeutics
April 05, 2023
Via
Benzinga
Preview: CymaBay Therapeutics's Earnings
March 15, 2023
Via
Benzinga
Analyst Expectations for CymaBay Therapeutics's Future
March 07, 2023
Via
Benzinga
Analyst Expectations for CymaBay Therapeutics's Future
February 08, 2023
Via
Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 24, 2023
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in...
Via
Benzinga
Why CymaBay Therapeutics Shares Are Rising
January 24, 2023
CymaBay Therapeutics Inc (NASDAQ: CBAY) shares are trading higher by 9.30% to $7.22 Tuesday morning. The company priced a public offering of common stock and pre-funded warrants at $7 per share and...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
January 23, 2023
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.